Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CEST

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
09/14 EDWARDS LIFESCIENCES : An Application for the Trademark "INTRACLUDE" Has Been Fi..
09/13 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Se..
09/07 EDWARDS LIFESCIENCES : business Edwards Lifesciences completes $100 million reno..
09/01 EDWARDS LIFESCIENCES : to Present at 12th Annual Wells Fargo Healthcare Conferen..
08/31 EDWARDS LIFESCIENCES : completes $100 million renovations of Irvine campus
08/31 EDWARDS LIFESCIENCES : To Present At The 12th Annual Wells Fargo Healthcare Conf..
08/19 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Au..
08/18 EDWARDS LIFESCIENCES : Sources Sought Notice - 65-- sources sought notice Edward..
08/17 EDWARDS LIFESCIENCES : Patent Application Titled "Systems for Placing a Coapting..
08/11 INSIDER TRADING ACTIVITY EDWARDS LIF : EW) – CEO Sold 32,900 shares of Sto..
More news
News from SeekingAlpha
09/20 M&A Deals Make The Market Interesting - Cramer's Mad Money (9/19/17)
09/01 Neovasc loses appeal in Tiara patent case, on the hook for $112M; shares down..
09/01 ZIMMER BIOMET HOLDINGS : Undervalued And Unloved
08/28 Premarket analyst action - healthcare
08/15 Edwards Lifesciences Stock To Remain Strong Ahead Of Robust Revenue And New P..
Financials ($)
Sales 2017 3 391 M
EBIT 2017 1 030 M
Net income 2017 796 M
Finance 2017 283 M
Yield 2017 -
P/E ratio 2017 30,11
P/E ratio 2018 27,36
EV / Sales 2017 6,81x
EV / Sales 2018 6,08x
Capitalization 23 363 M
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Technical analysis trends EDWARDS LIFESCIENCES CORP
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 131 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John T. Cardis Independent Director
William J. Link Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES CORP17.75%23 363
THERMO FISHER SCIENTIFIC INC.33.18%75 111
DANAHER11.02%60 285
BOSTON SCIENTIFIC CORPORATION33.33%39 586
ROYAL PHILIPS21.62%39 413
INTUITIVE SURGICAL62.45%38 322